Last reviewed · How we verify
Lantus, Amaryl
Lantus, Amaryl is a Insulin analog (Lantus); Meglitinide/Sulfonylurea (Amaryl) Small molecule drug developed by Sanofi. It is currently FDA-approved for Type 2 diabetes mellitus, Type 1 diabetes mellitus (Lantus). Also known as: insulin glargine,glimepiride.
Lantus is a long-acting basal insulin that lowers blood glucose by promoting glucose uptake and utilization in peripheral tissues and inhibiting hepatic glucose production, while Amaryl is a meglitinide that stimulates pancreatic beta cells to release insulin in response to meals.
Lantus is a long-acting basal insulin that lowers blood glucose by promoting glucose uptake and utilization in peripheral tissues and inhibiting hepatic glucose production, while Amaryl is a meglitinide that stimulates pancreatic beta cells to release insulin in response to meals. Used for Type 2 diabetes mellitus, Type 1 diabetes mellitus (Lantus).
At a glance
| Generic name | Lantus, Amaryl |
|---|---|
| Also known as | insulin glargine,glimepiride |
| Sponsor | Sanofi |
| Drug class | Insulin analog (Lantus); Meglitinide/Sulfonylurea (Amaryl) |
| Target | Insulin receptor (Lantus); ATP-sensitive potassium channel on pancreatic beta cells (Amaryl) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Lantus (insulin glargine) is a recombinant human insulin analog with a prolonged duration of action (up to 24 hours), providing steady basal insulin coverage. Amaryl (glimepiride) is a short-acting insulin secretagogue that binds to ATP-sensitive potassium channels on beta cells, triggering insulin secretion primarily during and after meals. Together, they provide both basal and prandial insulin coverage for glycemic control.
Approved indications
- Type 2 diabetes mellitus
- Type 1 diabetes mellitus (Lantus)
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions (Lantus)
- Headache (Amaryl)
- Dizziness (Amaryl)
Key clinical trials
- Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2) (PHASE3)
- Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005) (PHASE3)
- A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024) (PHASE3)
- A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007). (PHASE3)
- A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016) (PHASE3)
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
- Short-Term Intensive Insulin Therapy Induction of Long-term Glycemic Control (NA)
- Study To Evaluate Beta Cell Function and Glycemic Outcome by Intensive Insulin Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lantus, Amaryl CI brief — competitive landscape report
- Lantus, Amaryl updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Lantus, Amaryl
What is Lantus, Amaryl?
How does Lantus, Amaryl work?
What is Lantus, Amaryl used for?
Who makes Lantus, Amaryl?
Is Lantus, Amaryl also known as anything else?
What drug class is Lantus, Amaryl in?
What development phase is Lantus, Amaryl in?
What are the side effects of Lantus, Amaryl?
What does Lantus, Amaryl target?
Related
- Drug class: All Insulin analog (Lantus); Meglitinide/Sulfonylurea (Amaryl) drugs
- Target: All drugs targeting Insulin receptor (Lantus); ATP-sensitive potassium channel on pancreatic beta cells (Amaryl)
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Indication: Drugs for Type 1 diabetes mellitus (Lantus)
- Also known as: insulin glargine,glimepiride
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing